HDAC2 and cancer: For example, Entinostat (MS-275), which is currently in clinical trials for cancer treatment, selectively inhibits HDAC1, HDAC2, and HDAC3 with an IC50 of 0.54, 0.61, and 0.62 μM, respectively [25].